Regeneron’s anti-SARS-CoV-2 antibody cocktail has significantly reduced medical visits in ambulatory COVID-19 patients. The phase 2/3 clinical trial linked REGN-COV2 to a 57% decline in medical visits associated with COVID-19 in the 29 days after treatment.
One month ago, Regeneron shared data on the first 275 patients enrolled in the study. That update, which provided early evidence that REGN-COV2 reduces viral load, set Regeneron up to apply for FDA emergency use authorization. Now, Regeneron has shared data on an additional 525 patients to further elucidate the effect of REGN-COV2 on viral load and clinical endpoints.
The primary endpoint looked at average daily change in viral load through to Day 7 of the trial. In patients with a high viral load, REGN-COV2 drove a 0.68 log10 copies/mL greater reduction than the placebo. The effect was particularly pronounced over the first five days of the trial, over which period Regeneron linked REGN-COV2 to a tenfold reduction in viral load. A smaller, but still statistically significant, difference was seen in patients with all levels of viral load at baseline.